Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents

Archives of Pediatrics and Adolescent Medicine

Volumn 162, Issue 10, 2008, Pages 929-935

  McIntyre, Roger S ^a,b   Jerrell, Jeanette M ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORTHOSTATIC HYPERTENSION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; SYNCOPE; WEIGHT GAIN;

ADOLESCENT; AGE DISTRIBUTION; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTENSION, ORTHOSTATIC; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; METABOLIC DISEASES; OBESITY; ODDS RATIO; PROBABILITY; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 53849092347     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpedi.162.10.929     Document Type: Article

References (36)

1. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685.
2. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14(3):372-394.
3. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15(1):177-206.
4. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(suppl 3):28-36.
5. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46(6):687-700.
6. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771-791.
7. Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol. 2005;19(5):533-550.
8. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(suppl 7):29-40.
9. McClellan J, Sikich L, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2007;46(8):969-978.
10. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40(4):441-447.
11. Flynn JT. What's new in pediatric hypertension? Curr Hypertens Rep. 2001;3(6):503-510.
12. Baker S, Barlow S, Cochran W, et al. Overweight children and adolescents: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2005;40(5):533-543.
13. Strauss RS. Childhood obesity. Pediatr Clin North Am. 2002;49(1):175-201.
14. Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord. 2003;5(suppl 2):62-79.
15. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272.
16. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68(2-3):167-181.
17. Osby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850.
18. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158(8):753-759.
19. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17-25.
20. Patel NC, Crismon ML, Hoagwood K, Jensen P. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharmacol. 2005;15(2):270-284.
21. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with SSRI treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.
22. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14(3):175-182.
23. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10(20):2463-2475.
24. To SE, Zepf RA, Woods AG. The symptoms, neurobiology, and current pharmacological treatment of depression. J Neurosci Nurs. 2005;37(2):102-107.
25. Francis PD. Effects of psychotropic medications on pediatric electrocardiogram and recommendations for monitoring. Curr Opin Pediatr. 2002;14(2):224-230.
26. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113(4):762-769.
27. US Department of Health and Human Services. Public welfare: protection of human subjects. 45 CFR §46. Effective June 23, 2005.
28. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006;5(1):157-168.
29. Kelly DL, Love RC, Mackowick M, McMahon RP, Conley RR. Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol. 2004;14(1):75-85.
30. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry. 2004;65(5):686-689.
31. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287(3):356-359.
32. Perrin JM, Bloom SR, Gortmaker SL. The increase of childhood chronic conditions in the United States. JAMA. 2007;297(24):2755-2759.
33. McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry. 2002;63(suppl 3):15-20.
34. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101(3):277-288.
35. Holmberg SK, Kane C. Health and self-care practices of persons with schizophrenia. Psychiatr Serv. 1999;50(6):827-829.
36. Mark TL, Buck JA, Dilonardo JD, Coffey RM, Chalk M. Medicaid expenditures on behavioral health care. Psychiatr Serv. 2003;54(2):188-194.